Patient Information and Informed Consent
for Protocol No. CAIN457H2315

A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

INVESTIGATOR: Alireza Nami, MD
Joint and Muscle Research Institute
332 Lillington Ave.
Charlotte, NC 28204
TELEPHONE: (704) 377-1216 - 24-hour number
(704) 248-8577 - office number

Document type: Patient Information and Informed Consent

Based on: Original Protocol dated 30-SEP-2015

Release date: 17-Dec-2015

Informed consent

You are invited to join voluntarily in a clinical research study to find out if the drug secukinumab (AIN457) is safe and has beneficial effects in people who have non-radiographic axial Spondyloarthritis (nr-axSpA). This is a rheumatic disorder with inflammation in the spine and pelvis resulting in back pain, but without changes visible on X-rays in the lower spine and pelvis. Patients suffer from chronic lower back pain despite treatment with non-steroidal anti-inflammatory drugs (NSAID), disease-modifying antirheumatic drugs (DMARD) and/or potentially anti-tumor necrosis factor-alpha (anti-TNFα) medications.

Before you agree to join in this study, you need to know the risks and benefits so you can make an informed decision. This process is known as "informed consent".

This consent form tells you about the study that you may wish to join. Please read the information carefully and discuss it with anyone you want. This may include a friend or a relative. If you have questions please ask the Study Doctor or study staff to answer them.

Once you know about the study and the procedures that will be done, you will be asked to sign this consent form to join this study. Your decision to take part in this study is voluntary. That means that you can join this study if you want to, or not join if you do not want to. Joining or not joining will not affect your medical care. You are also free to stop study treatment and study-related activities at any time and without any reason. If you choose not to join in this study, you can discuss regular medical care with the Study Doctor.

Schulman Institutional Review Board, Inc. (Schulman) has approved the information in this consent document and has given approval for the study doctor to do the study. An institutional review board (IRB) is an independent committee established to help protect the rights of research subjects. This does not mean the IRB has approved your participation in the study. You must think about the information in this consent document for yourself. You must then decide if you want to be in the study.

At any time during the study, please tell your Study Doctor or study staff if you have any unusual symptom(s).

We will tell you about any new information that may affect your participation in the study. You can then decide if you want to continue study treatment and other study-related activities.

The Study Doctor may remove you from this study for any justified reason according to the protocol.

Examples why you may have to stop some or all study-related activities, including study treatment are:

1. You need treatment not allowed in this study.
2. You fail to follow instructions
3. You become pregnant
4. You experience side effects from the study treatment that you find unacceptable

5. Your study doctor considers keeping you in the study might be harmful to you
6. Novartis decides to stop the study or the development of the study treatment.

You may experience an increase in pain or symptoms of nr-axSpA with sudden discontinuation from study medication.

If you decide to stop study treatment and/or other study-related activities you should tell the Study Doctor or study staff. They will make sure that proper procedures are followed

Study Treatment

Secukinumab is a type of medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin-17A (IL-17A). IL-17A is believed to be partly responsible for inflammation (pain, swelling, redness) and research indicates that IL-17A causes symptoms of axSpA which is directly related to nr-axSpA. A medication that targets IL-17A therefore may help to relieve these symptoms and conditions. This is the reason why secukinumab was developed.

A pre-filled syringe with liquid formulation of secukinumab will be used in this study. It is requested that participants administer (inject) the study treatment by themselves ("Instructions For Use" and guidance to self-inject the study drug will be provided separately).

Study treatment (Secukinumab or Placebo) will be administered once a week for the first 4 weeks, followed by a monthly injection.

A **placebo** is a dummy drug with no active ingredients. A placebo is used to make sure the changes you report are not happening by chance.

You should only take the study treatment as instructed and should not do anything else with it.

You may discuss with a doctor or health care professional, who is not directly involved in the study, health issues or medical problems related to the study treatment or disclose information related to the study treatment.

At the end of the study or if you stop study treatment you should return any study treatment, that you still have remaining to the Study Doctor.

Trial purpose and conduct

This is a clinical research study. This trial is sponsored by the pharmaceutical company named Novartis (the "Sponsor"). Your study doctor is being paid by Novartis to conduct this study. If you agree to join in this study, you may get either secukinumab 150 mg or a placebo for the first 52 weeks of the study. At the start of the trial, there is a 2 to 1 chance of receiving either secukinumab or placebo with no medicine. After 20 weeks, your disease status will be assessed jointly by your doctor and you, and if it appears that you have not improved repeatedly and have been on placebo, you can switch to secukinumab 150 mg. You and your doctor will not

know what study treatment you have been given, but your doctor can find out what you were taking if there is an emergency. After 52 weeks, all patients who remained on study treatment will receive secukinumab 150 mg until the end of the treatment period of 100 weeks.

Secukinumab is a medicine which has not been approved by the US Food and Drug Administration for the treatment of people with your medical condition. The medicine being tested in this study is available "on the market" (available to buy) for other indications such as psoriasis in some countries (including the United States).

You have been asked to participate in this clinical research study because you have active non-radiographic spondyloarthritis that requires treatment. The disease of axial spondyloarthritis (axSpA) (either with or without visible radiographic changes) affects up to 1 in 100 people and causes significant illness and disability. In axSpA, the joints in the spine and in the bony pelvis become inflamed (the joints become swollen and/or tender). As a consequence, the joints in and around the spine can fuse together. AxSpA can also affect other tissues in the body. It can cause inflammation of the eyes, heart, lungs, kidneys and intestines. Several treatments exist for nr-axSpA. The existing treatments, however, may only partially control the disease, become less effective over time, or lead to side effects. The purpose of this study is to evaluate the effectiveness and safety of secukinumab (added onto certain current medicines you may have been taking, such as NSAIDs, methotrexate (MTX), sulfasalazine and/or systemic corticosteroid therapy) self-administered subcutaneously (under the skin) versus placebo (dummy drug).

So far, approximately 9600 subjects with a variety of diseases, as well as healthy volunteers, have received secukinumab at single or multiple doses in clinical studies. Approximately 555 patients will join in this study at approximately 150 centers worldwide. Your participation will last for two years (or 112 weeks, which includes the 8-week follow-up period plus an additional 4-10 weeks screening period) Participation will consist of 33 visits (24 visits at the study center and 9 home administration visits).

The following is a detailed description of the planned study periods and the procedures which will be carried out:

Screening Period Procedures

At the first study visit (called the screening visit) and after you agree to take part in the study, you will be asked about your health and medical history. The doctor will examine you and measure your height, weight, blood pressure, and heart rate. You will be asked about any medications you are taking now or have taken in the past. Blood and urine will be taken for laboratory testing. Hepatitis B and/or Hepatitis C and/or HIV blood testing may be performed during screening period only if required as per local medical practice or local regulations prior to the start of study treatment. Positive HIV and Hepatitis test results may be reportable to local health authorities according to local laws. Tests will be done for tuberculosis, and you may also have a chest x-ray or Magnetic Resonance Image (MRI) if you haven't had one in the last 3 months to make sure you don't have a lung disease. A diagnosis of TB may be

reportable to local health authorities according to local law. A MRI and two X-rays of your spine and pelvis will be done. If you had X-rays done in the past 3 months, they might be used instead. Based on the results of these images and additional checks done by the Study Doctor, the severity of your nr-axSpA will be assessed. Medicines you are taking before you start this study may be stopped. This is to avoid a mix-up of effects between your other medicines and the study treatment. This is called a washout period during which the effects of these medications leave your body. Depending on the medications you are currently taking, a second screening visit at the study center may be necessary as instructed by the Study Doctor.

If you are a woman who can get pregnant, your blood will be tested to see if you are pregnant. If you are pregnant, you will not be allowed to begin the study treatment and will have to stop your participation in the study.

The Study Doctor will review the results of the screening procedures and will tell you if you meet the requirements to continue participation in the study; if that is not the case, your participation will end after the screening period.

Study Treatment Periods

After it is confirmed that you meet the requirements to enter the study, you will attend a visit at the study center called the "baseline visit" within 4 weeks after the last screening visit. The Study Doctor will review any changes in your health since the previous visit and make sure you still qualify to take part in the study. Blood will be taken for laboratory testing. Additionally, you will be asked about your smoking and cardiovascular history and you will have an electrocardiogram (ECG).

If you qualify, you will be assigned by chance (i.e., like flipping a coin) to one of the three possible treatments of either secukinumab with or without loading doses or placebo. The chance to receive placebo is 1 in 3. You will receive the first dose of study treatment at the Baseline visit. You will be instructed by the study staff or your Study Doctor by reviewing the Instructions For Use (IFU) on how to self-inject the pre-filled syringe and will be given an opportunity to raise any questions. You will then be instructed to refer to the IFU and self-inject study treatment subcutaneously into the thigh or the lower abdomen, in the presence of the study staff. If a caregiver or member of the study staff is giving you your injection, they may also inject into your outer upper arm.

Following the Baseline visit, you will return to the study center at regular intervals, to have your condition monitored and to receive study medication. After Week 52, you will be given the option to self-inject study medication at home for some visits, as explained above.

If the Study Doctor or you feel that you are not benefiting from participating in the study, you may leave the study at any time.

The procedures and tests performed during the treatment period are listed below. If you would like more information about which tests and procedures will be done at each visit, please ask the Study Doctor or study staff.

- **Blood pressure, pulse:** Your blood pressure will be checked by putting a cuff around your arm. Your pulse (heart rate) will also be checked at each visit.
- **Weight:** Your weight will be measured at certain visits.
- **Physical exam:** At some visits, your general health and the status and severity of your nr-axSpA will be assessed through physical examination.
- **ECG:** An ECG or "electrocardiogram" is a test that measures the electrical activity of your heart using a special device. It will be recorded at some visits.
- **Questionnaires:** At some visits, you will be asked to complete questionnaires about your general health, your nr-axSpA, the pain you feel, and fatigue. You will enter your answers using an electronic tablet at the study center.
- **Flexibility and mobility:** Your flexibility and spinal movements will be measured at certain visits.
- **MRI and X-Ray:** To measure the effect of secukinumab on joint/bone inflammation and structural damage Magnetic Resonance Imaging (MRI) will be performed at screening, after week 16, week 52 and week 104. X-rays of your spine and pelvis will be performed at screening, then afterwards, at week 104, to assess structural bone damage, after two years, compared to the time before you entered the study.
- **Routine blood samples:** Blood samples will be drawn via a needle introduced in a forearm vein at some of the visits. The blood is used to do laboratory testing for your safety, including standard blood tests that show how your kidney and liver are working, and cell counts in your blood. In addition, certain proteins (called biomarkers) in your blood that can tell us about any ongoing inflammation will be tested. Your blood samples will also be used to measure whether your body creates antibodies that act against the study medication. The Study Doctor or study staff can tell you more about the different reasons for testing your blood.
- **Urine tests:** A urine specimen for the measurement of protein, glucose, blood, and white blood cells at the study center (by a method called dipstick) will be collected at scheduled visits. If you are a woman who can become pregnant, you will have several urine pregnancy tests. The Study Doctor or the study staff will tell you if the pregnancy test results are positive. To be able to remain in the study, the results of your pregnancy test must be negative.
- **Exploratory biomarkers (genetic tests, serum biomarker):** This study also has two optional blood tests. The first sample is collected to study the DNA sequence of certain genes (pharmacogenetics) in patients with nr-axSpA. A total of 10 mL (2 teaspoons) of blood is taken once in the beginning of the study (at the baseline visit). The second sample is collected to tell us more about the disease and how your body responds to the study drug, and is called serum biomarker test. If you agree to take part in either of these optional testing, you will be asked to sign a separate consent form (for genetic samples) and a separate consent page for (non-genetic biological samples). You do not have to participate in this additional testing in order to be in the main study. These optional tests are of no direct use

to you but may help improve the understanding of the disease and how patients respond to secukinumab treatment. The results of these optional tests will not be entered in your patient records. If you initially choose not to participate in this study but change your mind later, you can tell your Study Doctor later that you wish to take part. It is important to note the following:

a. If any samples remain after analysis, they may be stored for up to 15 years by Novartis to do more research on the study drug or the disease. These samples will be stored under the control of Novartis (the study sponsor); however during and after the study you are the owner of the samples. This gives you the right to have the sample material destroyed by Novartis at any time. If you choose to have your samples destroyed, please contact your Study Doctor. Any information which was generated prior to your request will not be deleted but no further studies will be performed
b. Novartis is responsible for the destruction of the samples at the end of the storage period. Novartis will be the exclusive owner of any data and discoveries resulting from this study. Any commercial product developed by Novartis as a result of this exploratory investigation would be based on the analysis of the samples collected, not of an individual sample of a subject.

The study treatment periods are completed on the Week 104 visit, which is 4 weeks after the last dose of study medication.

Follow-up period

The follow-up period begins with the Week 104 visit and continues until the Week 112 visit. No study medication will be taken during this period. At the Week 112 visit, the Study Doctor will examine you and also measure your weight, vital signs, and heart rate. Women of child-bearing potential will have a urine pregnancy test. Blood samples will be drawn as above and urine taken for laboratory assessment.

If you stop the study for any reason at any time during the treatment periods, you will also enter this follow-up period.

After finishing the 104 weeks of the study, you may have the option to join a study extension, which means that you would be able to continue to take the active study treatment for as long as the study is in progress. The set-up and duration of such an extension study will be determined based on multiple factors, including availability of the study treatment in your respective country.

Responsibilities of the patient

Related to study appointments/visits and procedures:

- You must comply strictly with the study procedures and the instructions given to you by the Study Doctor and the study staff.
- It is very important that you attend the planned visits at the study center regularly and on the dates indicated by the study staff. If it is necessary to miss an appointment, you must contact the Study Doctor or Study Staff to reschedule your appointment.
- Complete your required study activities as instructed, such as filling in questionnaires or diaries.
- Do not eat or drink anything except water or unsweetened tea, for 8 hours before the baseline visit as well as study visits Week 8, 16, 52 and 104.
- If you chose to do home administration in the second year, you need to contact the site staff before you administer the study drug, in case you are experiencing any adverse event or have any concerns.
- For all home administration visits, complete and return your diaries as instructed at the next site visit.

Related to study treatment:

If after the first year of participation you chose to self-administer the study medication at home, you must:

- Take the study treatment as the Study Doctor tells you to and should not do anything else with it. Do not miss any study treatment.
- Ensure proper storage of all supplies given to you, and keep them away from children and for your use only.
- At each site visit after the home administration visits, return all used and unused supplies to the study center.

You may discuss with a doctor or a health care professional who is not directly involved in the study, health issues or medical problems related to the study treatment or disclose information related to the study treatment.

Related to side effects and other medications you may be taking:

- Please tell your Study Doctor or the Study Staff if you have any unusual symptoms, any side effects, and other doctor visits or hospitalizations that you may have.
- You must tell the Study Doctor about any medications you are taking during the study, including prescriptions drugs, over-the-counter medicines and vitamins/supplements, and about changes in dose of any medications you are taking regularly.

It is extremely important that if you wish to become pregnant, you wait until you finished the study or longer if required by locally approved prescribing information.

By signing this consent form, you agree to follow the instructions of the Study Doctor, to attend all study-related visits on time, to complete all study tasks, to report changes in your health, and to take care of the study supplies given to you.

Biological Sample Collection

Blood will be taken to characterize how secukinumab is taken up, and retained in your body. The samples will be collected from screening to the end of the study. They may be used for measuring the amount of secukinumab and its degradation. Your body may produce proteins (called antibodies) that bind to secukinumab. It is possible that these proteins could reduce its effectiveness as a new medicine, and so you will be asked to provide blood samples that will be tested for these specific antibodies. The results of these tests will be used to better understand how your body responds to secukinumab.

The effectiveness of secukinumab is linked to its ability to bind a specific protein in your body. Blood samples will be taken to determine the amount of this molecule. This will be used to better understand the relationship between the dose of secukinumab and its effects on nr-axSpA.

You are also being asked to give blood and urine samples at certain times during the trial for additional tests called “biomarker analysis”. A “biomarker” is a measurement which gives information about your health or the effects of treatment on you. These biomarker tests will be used to study scientific questions related to secukinumab’s effect on cells or organs of your body, on changes in your disease status such as level of inflammation, and more generally, to understand your disease better.

Serum biomarker samples will be drawn at baseline, Weeks 16, 52, 104 and the follow-up visit at Week 112. Safety labs will be drawn at your second screening visit, baseline, Weeks 1, 2, 4, 8, 12, 16, 24, 28, 40, 52, 64, 76, 88, 104 and the follow-up visit at Week 112. Urine samples will be taken during your second screening visit and then at baseline, Weeks 1, 2, 4, 8, 12, 16, 24, 28, 40, 52, 64, 76, 88, 104 and the follow-up visit at Week 112.

Imaging

You need to have X-rays taken at the beginning and the end of the study, which will expose you to a small amount of radiation. This can carry very small risks, but the dose of radiation in the X-rays is low.

As MRIs are taken over the course of the trial, patients with pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body that render the patient unable to undergo MRI and patients who are unable to undergo MRI due to claustrophobia will be excluded from participation in the study.

Study treatment discontinuation

Please tell your Study Doctor or study staff if you decide to interrupt or stop taking the study treatment. You will be asked to return to the study center as soon as possible to check how you are. You should bring your study treatment and supplies to the clinic. Also, the Study Doctor may choose to discontinue your study treatment.

You may be asked to continue with study visits after stopping study treatment so that all or a selection of assessments can be performed. This will improve the study even if you do not continue to take the study medicine.

If you cannot or do not want to continue to attend study visits while off study treatment, your Study Doctor or study staff may ask if they can contact you by telephone until the end of the study to check how you are doing. You may decline contact by telephone if you so choose.

You will be given any new information as it becomes available that may affect your participation in the study. You can then decide if you want to continue study treatment and other study-related activities.

Withdrawal of your consent to participate in this study

You may decide that you not only want to stop study treatment but also don't want to come to any further visits, don't want to have any further assessments or contact by the Study Doctor nor Study Staff, and don't want to allow Novartis to further analyze any blood or other biological samples already taken. This is considered as withdrawal of your consent from participation in this study. It is important that you inform your Study Doctor *(in writing)*.

Novartis will continue to keep and use any research results that have already been collected for the study, but no further study-related activities will take place.

You can discuss further regular medical care with the Study Doctor. The choice to withdraw from research participation will not affect your medical care.

Risks and inconveniences

Any research has some risks. You may experience possible side effects from the study drug.

Possible side effects of the treatment include:

Side effect	Frequency
Upper respiratory tract infections with common cold, stuffy nose (nasopharyngitis, rhinitis) being the most frequent	Very common(in more than 1 in 10 patients)
• Cold sores (oral herpes) • Runny nose (rhinorrhea) • Diarrhea • Itchy rash (urticaria)	Common (in more than 1 in 100 but fewer than 1 in 10 patients)
• Oral yeast infection (oral candidiasis) • Athlete's foot (tinea pedis) • Low levels of a type of white blood cell (neutropenia) • Red eye which may be accompanied by watering and itching (conjunctivitis)	Uncommon (in more than 1 in 1,000 but fewer than 1 in 100 patients)

Since secukinumab is a drug that may have the potential to suppress your immune system, you may be at increased risk for infections.

You should seek medical advice if you develop signs or symptoms suggestive of an infection such as fever. Your doctor should monitor your medical condition and evaluate the benefits and risks of your continuation in the study.

Worsening of Crohn's disease, in some cases serious, was observed in clinical studies in both secukinumab and placebo groups. If you have Crohn's disease, please make sure you make your doctor aware.

If you ever had an allergic reaction to latex, please inform your doctor.

It is possible that some people could have an allergic reaction to secukinumab. Some allergic reactions can be life-threatening. These reactions may occur immediately after a dose or many days later. During your visit to the Study Doctor's office, you will be monitored for immediate reactions after each dose of secukinumab. Allergic reactions cause rash or itching; trouble breathing or wheezing; a drop in blood pressure; swelling around the throat, mouth, and eyes; a fast heart pulse; fever; sweating; or chills. If you have an episode with these symptoms, you should get medical help immediately from the Study Doctor. If it is not possible to contact the Study Doctor immediately, please go to an emergency room as soon as possible.

The study medicine may affect the response to certain vaccinations. Live vaccines should not be given concurrently with secukinumab. **It is your responsibility to discuss with your Study Doctor beforehand any plan of ANY vaccinations since certain vaccinations must not be given while you are taking the study medicine.**

It is also possible that secukinumab will not help your nr-axSpA. Your Study Doctor will assess your nr-axSpA at your visits and can advise you if you should leave the study if you have no improvement or if your symptoms worsen.

Problems or side effects that are not now known to date could also occur. You will be given any new information that may affect your willingness to start or continue in the study.

Here are important points about your side effects:

- Your Study Doctor cannot predict who will or will not have side effects.
- Some side effects may go away soon, some may last a long time, or some may never go away.
- Some side effects may interfere with your ability to have children.
- Some side effects may be serious and may even result in death.

Here are important points about how you and the Study Doctor can make side effects less of a problem:

- Tell the Study Doctor if you notice or feel anything different.
- The Study Doctor may treat side effects or adjust the study treatment to try to reduce side effects.
- Ask your Study Doctor for more information about potential risks and side effects from study treatment.

There are also some known risks, although rare, with taking blood. The tests done at each visit are standard medical tests. The risks of taking blood may include fainting, bleeding, pain and/or bruising. Rarely, these risks may be a small blood clot or infection at the site of the needle puncture.

Blood will be taken approximately 23 times during the study and approximately 5 to 30 mL (or about 1 to 6 teaspoons) of blood will be collected each time. During the first month of the study, the amount of blood taken in total will be around 65 mL (or less than 5 tablespoons). After this initial month, the monthly amount will not be more than 30 mL.

When measuring blood pressure, the blood pressure cuff may cause discomfort or bruising to the upper arm.

In rare instances where a nurse, a doctor, or a laboratory technician, is exposed to your blood, tissue or body fluids by needle stick, cut or splash to mucosa or damaged skin, it may be necessary to test your blood, tissue, or body fluid sample for certain viral infections including

Hepatitis B and C and HIV on the sample already available. This is to make it possible for that person to receive appropriate counseling, monitoring and treatment that they may need. In this instance the Study Doctor will tell you the results of these tests and advise you on the next steps. Confidentiality of the results of your tests will be respected at all times.

You will be given a small amount of radiation for the X-rays performed in this study. This can carry very small risks, but the dose of radiation in the study X-rays (chest X-ray at screening, spine and pelvis X-ray at inclusion and after two years) is low - the same as 1 year of normal radiation received in everyday life, depending on the body part. **You should inform the physician or technician if you are pregnant, or suspect to be, as this exam may cause harm to unborn babies.** Your physician or technician can explain the procedure and risks in greater detail and clarify any concerns or questions.

If a skin test is done for tuberculosis testing, it may cause some swelling and hardness at the injection site.

Skin irritation is rare but could occur during an ECG from the electrodes or gel that is used.

During the washout phase, you will not be receiving medication for your condition and your condition may become worse, stay the same or improve.

Contraception and Pregnancy

Women who are pregnant or nursing a child cannot participate in this trial. You must confirm, to the best of your knowledge, that you are not now pregnant, and that you do not intend to become pregnant during the entire trial or longer if required by locally approved prescribing information.

Animal studies have shown so far that none of the medications you are required to take in this study does harm to an unborn or nursing baby. Nonetheless, as a precaution you are required as a female participant in the study not to become pregnant. It is therefore important that you use an effective form of birth control (contraception) if you are sexually active and may become pregnant. You may choose to use an occlusive cap (diaphragm or cervical/vault cap) or your male partner to use a condom combined with a spermicidal foam/gel/film/cream/vaginal suppository. The following methods are more effective and are also acceptable: (1) total abstinence from male/female intercourse, or (2) male/female sterilization, or (3) use of oral, injected or implanted hormonal methods of contraception (in case of oral contraception, you should have been using the same pill on a stable dose for a minimum of 3 months before taking study treatment), or (4) placement of an intrauterine device (IUD) or intrauterine system (IUS).

Please discuss with your Study Doctor the most appropriate birth control method for you that also respects your cultural and religious situation.

If you become pregnant or suspect being pregnant during study or longer if required by locally approved prescribing information, you must inform the Study Doctor immediately and stop ongoing study treatment immediately. You will not be allowed to continue study treatment if

you are pregnant. Your Study Doctor will medically follow your pregnancy until delivery to monitor you and your child's safety.

General Information on pregnancy and contraception

85 out of 100 sexually active women who do not use birth control can expect to become pregnant in a year. No matter which birth control you are using from the list above, it is important to follow the manufacturer directions. If you don't, you raise your chance of getting pregnant.

Hormonal contraception is available in the form of pills which need to be taken every day, injections, which lasts approximately 3 months and as implanted devices. Hormonal methods are associated with some risks like changes in your cycle, nausea, headache, changes in mood, weight gain, breast tenderness, and blood clots.

Implanted devices are inserted into the uterus and can stay there for several years. They can cause cramps, bleeding, and infertility. It is important to know that not all women experience all of the adverse effects listed above.

Benefits of treatment

You may benefit as a result of your participation in this study. There is, however, no guarantee that you will benefit from your participation in this study.

In addition to a potential treatment effect, information from this study may help you and/or other people with nr-axSpA.

Alternative procedures or treatment

Other medicines are used in patients with nr-axSpA, specifically NSAIDs, DMARDs, *and anti-TNFα agents*. You can ask your doctor about their potential benefits and risks.

Costs for participation in this study

There will be no monetary costs to you for participating in this study. You will not be charged for the study drug(s) or any of the tests and procedures performed solely for research purposes.

Compensation for participation in this study

For your time and inconvenience related to your participation in this study, you will be paid for the study visits you complete according to the following schedule: $45.00 for each completed visit with the exception of visits 16, 52 and 104 which will be compensated in the amount of $86.00. At completion of the study this will be an overall total of $1203.00. If you do not complete the study, for any reason, you will be paid for each study visit you do complete according to the schedule above.

You will be paid after each completed visit.

If you have any questions regarding your compensation for participation, please contact the study doctor at the telephone number listed on page one of this consent document.

Compensation for injury resulting from the study

If the study was done correctly and you may have been harmed by the study drug, Novartis will pay for all reasonable medical bills that your insurance company does not pay. These are the only bills that Novartis will voluntarily pay. If the Study Site or someone who works for them caused your harm, Novartis will not pay your medical bills. If you are hurt because you did not follow instructions, Novartis will not voluntarily pay your medical bills. If your disease or the treatment of your disease caused your harm, Novartis will not voluntarily pay your medical bills.

Tell the Study Doctor if you think that being a patient in this study has caused you to be harmed. The Study Doctor listed on page 1 of this consent will tell you how you can get medical care for your problem and how to receive it.

You will not lose any of your legal rights or release the Sponsor, the study doctor, the study staff, or study site from liability for mistakes or intentional misconduct by signing this consent document.

Confidentiality and Authorization to collect, use and disclose Personal Medical Information

For purposes of this study, the study doctor and the study doctor's institution will use medical information collected or created as part of the study, such as medical records and test results that identifies you by name or in another way. Your consent to participate in the study means you agree that the study doctor and the study doctor's institution may obtain your medical information that they request for study purposes from your physicians and your other health care providers. You are also agreeing that the study site may use and share this information with the parties described below. In addition, you agree that, during the study, you may not have access to some of your medical information obtained or created as part of this study. You will be allowed to access this information once the study is finished.

Records of your participation in this study will be held confidential except when sharing the information is required by law or as described in this informed consent. This means that absolute confidentiality cannot be guaranteed. If the results of this study are published or presented at meetings, you will not be identified.

Unless required by law, the study site will share this medical information only with the Study Team and other professionals involved in the Study, Novartis Pharmaceuticals Corporation (the study sponsor) and its authorized agents, assignees, subsidiaries, affiliates, licensees, and contractors, the US Food and Drug Administration (FDA), governmental agencies in other countries where the study drug may be considered for approval, and the Institutional Review Board. The purpose for using and sharing this information with these parties is to perform the study and to ensure the accuracy of the study data. Not all of the parties who will have access to your medical information as part of the study are prohibited by federal law from further sharing it, so the information, once received by them, may no longer be protected by federal law.

Novartis may share your information with other members of the Novartis worldwide group of related companies, and people and companies who are collaborating with Novartis in connection with this study or with the study drug, ethics committees, Institutional Review Boards, regulatory agencies in the United States and internationally, and as otherwise permitted or required by law. During the study or at any time in the future, Novartis may decide to transfer all or some of (i) its rights to the study drug to another company or companies, and/or (ii) its rights and responsibilities as Sponsor to another company. If Novartis makes either of these transfers, it is possible that Novartis will share your information with these companies. Once these companies have your information, it is possible that they will share it further.

You have the right to cancel this authorization at any time by giving written notice to Study Doctor listed on page one of this consent. If you cancel this consent, then the study site will no longer use or disclose your medical information, unless it is necessary to do so to preserve the scientific integrity of the study. However, canceling this consent will not affect previous uses and disclosures and your medical information would not be removed from the study records.

If you fail to give your authorization by signing this document, or if you cancel your authorization later, then you will be not be eligible to participate in this study and will not receive any treatment provided as part of the study. Your HIPAA Authorization will expire 50 years from the date you sign it unless you revoke (cancel or withdraw) it sooner.

A description of this clinical trial will be available at http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

Primary Care Physician/Specialist Notification

Please indicate below whether you want us to notify your primary care physician or your specialist of your participation in this study.

_____ Yes, I want the study doctor to inform my primary care physician/specialist of my participation in this study.

_____ No, I do not want the study doctor to inform my primary care physician/specialist of my participation in this study.

_____ I do not have a primary care physician/specialist.

_____ The study doctor is my primary care physician/specialist.

Contacts

If you have questions about the research, please contact the Study Doctor listed on page one of this consent document.

If you have questions related to your rights as a research subject, please write to Schulman Institutional Review Board, Inc. 4445 Lake Forest Drive - Suite 300, Cincinnati, Ohio 45242, or call toll-free 1-888-557-2472 during business hours Monday - Friday 8:00 a.m. to 6:00 p.m. EST.

In the event of a research-related injury, please contact the Study Doctor listed on page one of this document.

Signature page

Protocol number: CAIN457H2315

Protocol title: A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

I have read this document/had its contents explained to me. I understand the purpose of this study and what will happen to me in this study. I have had an opportunity to ask questions and all of my questions have been answered to my satisfaction. I do freely give my consent to join in this study, as described to me in this document. I understand that I will receive a copy of this document as signed below.

By signing this form I have not given up any of my legal rights as a research participant.

type/print name Subject	Signature	Date
type/print name Investigator	Signature	Date
type/print name Name of presenter (who presented/explained the document)	Signature	Date

Signature page: Optional Serum Biomarker Test

Protocol number: CAIN457H2315

Protocol title: A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

I have read this document/had its contents explained to me. I understand the purpose of this study and what will happen to me in this study. I do freely give my consent to join in this study, as described to me in this document. I understand that I will receive a copy of this document as signed below.

By signing this form I have not given up any of my legal rights as a research participant.

type/print name Subject	Signature	Date
type/print name Investigator	Signature	Date
type/print name Name of presenter (who presented/explained the document)	Signature	Date